Interim report for Q3 2017
We can now put eight quarters of rising sales based on rolling twelve-month figures behind us, which is very positive. This means that more and more patients have access to effective and safe infection prevention, not least in Sweden where we have recently won another tender. The value of delivered products increased by close to 50% in the quarter. Total revenues were essentially unchanged, but increased by 19% for the full nine-month period. EBITDA earnings were lower in the third quarter, but more than doubled for the nine-month period. At the same time, we generated a very strong cash flow